ICU Medical Q1 revenue and profit beat estimates despite divestiture
ICU Medical, Inc. ICUI | 0.00 |
Overview
U.S. medical device maker's Q1 revenue beat analyst expectations despite 12% yr/yr decline post-divestiture
Adjusted EPS and adjusted EBITDA for Q1 beat analyst expectations
Company's gross margin rose to 39% from 35% yr/yr, driven by product mix and divestiture
Outlook
Company did not provide specific guidance or outlook for the current quarter or full year
Result Drivers
DIVESTITURE IMPACT - Revenue decline primarily reflects the strategic divestiture of the IV Solutions business in May 2025
PRODUCT LINE PERFORMANCE - Consumables and Infusion Systems posted year-over-year revenue growth, while Vital Care declined due to the IV Solutions divestiture
Company press release: ID:nGNX88Qsk7
Key Details
Metric |
Beat/Miss |
Actual |
Consensus Estimate |
Q1 Revenue |
Beat |
$530.23 mln |
$520.48 mln (6 Analysts) |
Q1 Adjusted EPS |
Beat |
$1.97 |
$1.75 (6 Analysts) |
Q1 Adjusted EBITDA |
Beat |
$98.70 mln |
$96.13 mln (6 Analysts) |
Q1 Gross Margin |
|
39.00% |
|
Q1 Gross Profit |
|
$206.23 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for ICU Medical Inc is $180.00, about 50.5% above its May 6 closing price of $119.59
The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 19 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.